Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | BMC Immunology

Fig. 1

From: Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer

Fig. 1

Flow Diagram: Enrollment, Assignment and Retention of Study Participants. 21 patients with non-small cell lung cancer were enrolled. Four fixed-dose groups (0.6 mg, 1.2 mg, 1.8 mg, and 2.4 mg) were set. Three patients were allocated to the 0.6 mg dose group, and received injection on days 4, 18, 32, 46 and 76 (5 vaccine dose). Six patients allocated to the 1.2 mg, 1.8 mg, 2.4 mg dose group separately and received the injection on the same dose intervals

Back to article page